Emergent BioSolutions Inc. is accusing disgruntled shareholders of concocting a phony securities fraud case over statements surrounding the company’s contamination of millions of Covid-19 vaccine doses.
“This case is a textbook example of an attempt to reverse-engineer a securities fraud case from an unfortunate business development,” Emergent said in its request to dismiss litigation filed against it.
The litigation stems from findings that staff at the company’s Bayview facility mixed AstraZeneca vaccine components into a Johnson & Johnson vaccine batch. Shares in the company fell after.
The move to dismiss comes shortly after the release of a congressional report suggesting ...